[8-K] TELA Bio, Inc. Reports Material Event
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.
TELA Bio, Inc. ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso il 30 giugno 2025 e ha fornito una presentazione aziendale aggiornata per gli incontri con gli investitori. Il Form 8-K indica le voci di divulgazione rilevanti come Item 2.02 (risultati operativi e situazione finanziaria) e Item 7.01 (Regulation FD disclosure) e elenca gli exhibit, tra cui il comunicato stampa (Exhibit 99.1), la presentazione (Exhibit 99.2) e la copertina Inline XBRL (Exhibit 104). Il deposito precisa che tali materiali sono forniti, non depositati e il documento è firmato dal CEO Antony Koblish. Le azioni ordinarie della società sono negoziate sul Nasdaq con il simbolo TELA e il registrante dichiara lo status di emerging growth company.
TELA Bio, Inc. publicó un comunicado de prensa con sus resultados financieros del trimestre concluido el 30 de junio de 2025 y facilitó una presentación corporativa actualizada para reuniones con inversores. El Formulario 8-K identifica los apartados de divulgación relevantes como Item 2.02 (resultados de operaciones y situación financiera) y Item 7.01 (Regulation FD disclosure), y enumera los anexos, entre ellos el comunicado de prensa (Exhibit 99.1), la presentación (Exhibit 99.2) y la portada Inline XBRL (Exhibit 104). El informe señala que estos materiales se entregan, no se archivan y el documento está firmado por el CEO Antony Koblish. Las acciones ordinarias de la compañía cotizan en Nasdaq bajo el símbolo TELA y el registrante declara su condición de emerging growth company.
TELA Bio, Inc.는 2025년 6월 30일로 종료된 분기 실적을 보고하는 보도자료를 배포하고 투자자 미팅용으로 업데이트된 기업 슬라이드 자료를 제공했습니다. Form 8-K는 관련 공시 항목을 Item 2.02(영업실적 및 재무상태)와 Item 7.01(Regulation FD 공시)로 지정하고, 보도자료(Exhibit 99.1), 슬라이드 자료(Exhibit 99.2) 및 Inline XBRL 표지(Exhibit 104)를 포함한 첨부물을 나열합니다. 제출 문서는 이러한 자료가 제출된 것이 아니라 제공된 것임을 명시하며 문서에는 CEO Antony Koblish의 서명이 포함되어 있습니다. 회사의 보통주는 나스닥에서 기호 TELA로 거래되며, 등록자는 emerging growth company 지위를 표시하고 있습니다.
TELA Bio, Inc. a diffusé un communiqué de presse présentant ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni une présentation d'entreprise mise à jour pour les réunions investisseurs. Le formulaire 8-K identifie les éléments de divulgation pertinents comme l'Item 2.02 (résultats d'exploitation et situation financière) et l'Item 7.01 (Regulation FD disclosure), et énumère les annexes, notamment le communiqué de presse (Exhibit 99.1), la présentation (Exhibit 99.2) et la page de garde Inline XBRL (Exhibit 104). Le dépôt précise que ces documents sont fournis, non déposés et le document est signé par le PDG Antony Koblish. Les actions ordinaires de la société sont négociées sur le Nasdaq sous le symbole TELA et l'émetteur indique son statut d'emerging growth company.
TELA Bio, Inc. hat eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht und ein aktualisiertes Unternehmens-Slide-Deck für Investorengespräche bereitgestellt. Das Form 8-K nennt die relevanten Offenlegungspunkte als Item 2.02 (Ergebnisse der Geschäftstätigkeit und finanzielle Lage) und Item 7.01 (Regulation FD disclosure) und listet Anlagen, darunter die Pressemitteilung (Exhibit 99.1), das Slide-Deck (Exhibit 99.2) und die Inline-XBRL-Titelseite (Exhibit 104). Die Einreichung stellt klar, dass diese Unterlagen bereitgestellt, nicht eingereicht wurden, und das Dokument ist vom CEO Antony Koblish unterzeichnet. Die Stammaktien des Unternehmens werden an der Nasdaq unter dem Symbol TELA gehandelt, und der Einreicher gibt den Status als emerging growth company an.
- Furnished a press release announcing financial results for the quarter ended June 30, 2025 (Exhibit 99.1)
- Provided an updated corporate slide deck for investor meetings (Exhibit 99.2)
- None.
Insights
TL;DR: Routine earnings disclosure; no financial figures included in this filing—materials are furnished for investor review.
The Form 8-K discloses that TELA furnished a press release with quarterly results and an updated investor slide deck, but it does not include the underlying financial statements or metrics within the filing itself. Because the materials are marked as "furnished, not filed," they carry standard disclosure intent but limited Section 18 liability. Investors should review Exhibits 99.1 and 99.2 for details; the 8-K alone provides notice of the update rather than substantive financial data.
TL;DR: Standard disclosure practice; Regulation FD slide deck provided and CEO attested to the filing—no governance red flags in this form.
The 8-K records an update under Regulation FD and furnishes a slide deck for investor presentations, reflecting routine investor communications. The filing explicitly states the materials are furnished rather than filed, which limits incorporation and liability under Section 18. The form is signed by the CEO, indicating authorized disclosure. The document also confirms the issuer’s Nasdaq listing (ticker TELA) and emerging growth company status, which can affect disclosure transition provisions.
TELA Bio, Inc. ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso il 30 giugno 2025 e ha fornito una presentazione aziendale aggiornata per gli incontri con gli investitori. Il Form 8-K indica le voci di divulgazione rilevanti come Item 2.02 (risultati operativi e situazione finanziaria) e Item 7.01 (Regulation FD disclosure) e elenca gli exhibit, tra cui il comunicato stampa (Exhibit 99.1), la presentazione (Exhibit 99.2) e la copertina Inline XBRL (Exhibit 104). Il deposito precisa che tali materiali sono forniti, non depositati e il documento è firmato dal CEO Antony Koblish. Le azioni ordinarie della società sono negoziate sul Nasdaq con il simbolo TELA e il registrante dichiara lo status di emerging growth company.
TELA Bio, Inc. publicó un comunicado de prensa con sus resultados financieros del trimestre concluido el 30 de junio de 2025 y facilitó una presentación corporativa actualizada para reuniones con inversores. El Formulario 8-K identifica los apartados de divulgación relevantes como Item 2.02 (resultados de operaciones y situación financiera) y Item 7.01 (Regulation FD disclosure), y enumera los anexos, entre ellos el comunicado de prensa (Exhibit 99.1), la presentación (Exhibit 99.2) y la portada Inline XBRL (Exhibit 104). El informe señala que estos materiales se entregan, no se archivan y el documento está firmado por el CEO Antony Koblish. Las acciones ordinarias de la compañía cotizan en Nasdaq bajo el símbolo TELA y el registrante declara su condición de emerging growth company.
TELA Bio, Inc.는 2025년 6월 30일로 종료된 분기 실적을 보고하는 보도자료를 배포하고 투자자 미팅용으로 업데이트된 기업 슬라이드 자료를 제공했습니다. Form 8-K는 관련 공시 항목을 Item 2.02(영업실적 및 재무상태)와 Item 7.01(Regulation FD 공시)로 지정하고, 보도자료(Exhibit 99.1), 슬라이드 자료(Exhibit 99.2) 및 Inline XBRL 표지(Exhibit 104)를 포함한 첨부물을 나열합니다. 제출 문서는 이러한 자료가 제출된 것이 아니라 제공된 것임을 명시하며 문서에는 CEO Antony Koblish의 서명이 포함되어 있습니다. 회사의 보통주는 나스닥에서 기호 TELA로 거래되며, 등록자는 emerging growth company 지위를 표시하고 있습니다.
TELA Bio, Inc. a diffusé un communiqué de presse présentant ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni une présentation d'entreprise mise à jour pour les réunions investisseurs. Le formulaire 8-K identifie les éléments de divulgation pertinents comme l'Item 2.02 (résultats d'exploitation et situation financière) et l'Item 7.01 (Regulation FD disclosure), et énumère les annexes, notamment le communiqué de presse (Exhibit 99.1), la présentation (Exhibit 99.2) et la page de garde Inline XBRL (Exhibit 104). Le dépôt précise que ces documents sont fournis, non déposés et le document est signé par le PDG Antony Koblish. Les actions ordinaires de la société sont négociées sur le Nasdaq sous le symbole TELA et l'émetteur indique son statut d'emerging growth company.
TELA Bio, Inc. hat eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 veröffentlicht und ein aktualisiertes Unternehmens-Slide-Deck für Investorengespräche bereitgestellt. Das Form 8-K nennt die relevanten Offenlegungspunkte als Item 2.02 (Ergebnisse der Geschäftstätigkeit und finanzielle Lage) und Item 7.01 (Regulation FD disclosure) und listet Anlagen, darunter die Pressemitteilung (Exhibit 99.1), das Slide-Deck (Exhibit 99.2) und die Inline-XBRL-Titelseite (Exhibit 104). Die Einreichung stellt klar, dass diese Unterlagen bereitgestellt, nicht eingereicht wurden, und das Dokument ist vom CEO Antony Koblish unterzeichnet. Die Stammaktien des Unternehmens werden an der Nasdaq unter dem Symbol TELA gehandelt, und der Einreicher gibt den Status als emerging growth company an.
FAQ
What did TELA report in this Form 8-K?
Are the press release and slide deck filed or furnished?
Which exhibits are included with the filing?
Which disclosure items does this Form 8-K address?
Who authorized or signed the Form 8-K?
